|Post IPO Valuation|
|Venture Round, 8/10 |
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases. It focuses on the development of antivirals for the treatment of HIV infection and chronic hepatitis C; and antibacterials for the treatment of serious hospital-based bacterial infections.
The companyâ€™s lead drug candidate is elvucitabine, an antiviral in phase II clinical trials for the treatment of HIV infection. It also develops ACH-702, a preclinical candidate for the treatment of serious hospital-based bacterial infection; and NS4A Antagonists, a preclinical-stage program for chronic hepatitis C. The company has research collaboration with Gilead Sciences, Inc. to develop and commercialize compounds for the treatment of chronic hepatitis C.
Achillion was founded in 1998 and is based in New Haven, Connecticut.